GPGrossPatternRESEARCH SYSTEM
SEC CHECK OPERATIONAL
GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME

VRCA · Jun 30, 2026

Verrica Pharmaceuticals Inc.. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.

STATE CAPABILITYLEVEL 3[email protected]
Inspectable configuration

State dimensions

Filing0001660334-26-000025General Corporate
Operating cash generation73thOwn-history percentile · N=11
Evidence method

Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue

-158.27% · OPTIONAL · VALID

Revenue growthRAWCurrent state valid · history insufficient
Evidence method

Yoy · gp.fundamentals.revenue

-53.85% · CORE · NOT_ENOUGH_HISTORY

Inventory pressure73thOwn-history percentile · N=11
Evidence method

Level · gp.fundamentals.inventory_revenue_ratio

46.26% · OPTIONAL · VALID

Operating margin58thOwn-history percentile · N=12
Evidence method

Level · gp.fundamentals.operating_margin

-223.42% · CORE · VALID

R&D intensity55thOwn-history percentile · N=11
Evidence method

Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue

102.93% · OPTIONAL · VALID

SBC intensity42thOwn-history percentile · N=12
Evidence method

Level · gp.fundamentals.sbc_revenue_ratio

20.69% · OPTIONAL · VALID

As-filed lineage

Fundamental state history

Each observation is tied to the filing and facts available at that report date. Amendments remain separate.

History11 statesHistory building
Sep 30, 20230/8 normalizedLevel 3Dec 31, 20230/8 normalizedLevel 3Mar 31, 20240/8 normalizedLevel 3Jun 30, 20240/9 normalizedLevel 3Sep 30, 20240/5 normalizedLevel 3Dec 31, 20240/9 normalizedLevel 3Mar 31, 20250/8 normalizedLevel 3Jun 30, 20252/7 normalizedLevel 3Dec 31, 20257/8 normalizedLevel 3Mar 31, 20265/6 normalizedLevel 3Jun 30, 20265/6 normalizedLevel 3
Period transition

What moved in the state?

Cash Generation Increased
Previous
-182.42%
Current
-158.27%
Delta
24.15%
Growth Decreased
Previous
46.06%
Current
-53.85%
Delta
-99.91%
Inventory Pressure Increased
Previous
39.30%
Current
46.26%
Delta
6.96%
Profitability Decreased
Previous
-193.41%
Current
-223.42%
Delta
-30.01%
R And D Intensity Increased
Previous
76.85%
Current
102.93%
Delta
26.09%
Sbc Intensity Increased
Previous
17.86%
Current
20.69%
Delta
2.83%
Self-history only

Previous similar states

Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.

Not enough compatible prior states for a transparent self-history match.
Research Graph

Related governed research

Compared To · Pharmaceutical Preparations peers →Has State · Verrica Pharmaceuticals Inc. →Transitioned To · VRCA Fundamental State →Transitioned To · VRCA CASH_GENERATION_INCREASED →Transitioned To · VRCA GROWTH_DECREASED →Transitioned To · VRCA INVENTORY_PRESSURE_INCREASED →Transitioned To · VRCA PROFITABILITY_DECREASED →Transitioned To · VRCA R_AND_D_INTENSITY_INCREASED →Transitioned To · VRCA SBC_INTENSITY_INCREASED →

Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.